Analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to announce earnings of $4.69 per share for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $5.19 and the lowest estimate coming in at $4.16. Regeneron Pharmaceuticals posted earnings of $4.17 per share during the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The business is expected to issue its next quarterly earnings results on Thursday, August 2nd.
On average, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $18.94 per share for the current year, with EPS estimates ranging from $17.75 to $20.36. For the next fiscal year, analysts expect that the firm will report earnings of $21.14 per share, with EPS estimates ranging from $18.55 to $23.25. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.08 by ($0.41). Regeneron Pharmaceuticals had a net margin of 23.54% and a return on equity of 29.92%. The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the previous year, the business posted $2.92 EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis.
Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday. SunTrust Banks set a $344.00 price objective on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday. BidaskClub upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. Oppenheimer upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $325.00 price objective on the stock in a research report on Wednesday, June 27th. Finally, UBS Group upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Wednesday, June 27th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $420.68.
In other news, Chairman P Roy Vagelos sold 74,710 shares of the business’s stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $327.87, for a total value of $24,495,167.70. Following the transaction, the chairman now directly owns 553,121 shares of the company’s stock, valued at approximately $181,351,782.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Sanofi sold 121,601 shares of the business’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $309.31, for a total value of $37,612,405.31. The disclosure for this sale can be found here. Insiders sold a total of 214,718 shares of company stock worth $67,470,695 in the last quarter. Corporate insiders own 12.42% of the company’s stock.
Several large investors have recently made changes to their positions in REGN. Loomis Sayles & Co. L P lifted its stake in shares of Regeneron Pharmaceuticals by 34.2% in the 1st quarter. Loomis Sayles & Co. L P now owns 2,819,755 shares of the biopharmaceutical company’s stock valued at $971,011,000 after purchasing an additional 718,144 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Regeneron Pharmaceuticals by 516.8% in the 4th quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock valued at $217,892,000 after purchasing an additional 485,600 shares during the period. Old Mutual Global Investors UK Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 157.3% in the 1st quarter. Old Mutual Global Investors UK Ltd. now owns 640,823 shares of the biopharmaceutical company’s stock valued at $220,673,000 after purchasing an additional 391,788 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $143,255,000. Finally, HealthCor Management L.P. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $122,187,000. 66.22% of the stock is currently owned by institutional investors.
Shares of Regeneron Pharmaceuticals opened at $360.95 on Tuesday, according to MarketBeat. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $526.12. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.94 and a current ratio of 3.59. The firm has a market capitalization of $38.11 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 1.27 and a beta of 1.36.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.